Zvi is a myeloma patient and an active member of the organisation AMEN (Israel). He has graduated in Computer Science from the Technion, Israel Institute of Technology and has a master’s in MBA with distinction from Derby University. He is a Software engineer with 25 years of experience in the fields of development, marketing, and program management in various hi-tech companies. For the last ten years, Zvi has worked for Intel Israel. He aims to improve early diagnosis of myeloma. In addition, he is willing to strengthen patient organisations across Europe by sharing knowledge and information. Zvi completed the MPE Advocate Development Program (ADP) in 2021.
EMA committee recommends teclistamab plus daratumumab for relapsed or refractory multiple myeloma
On 25 June 2026, the Committee for Medicinal Products for Human Use (CHMP) recommended extending the approved use of teclistamab (Tecvayli®) to include its use in combination with daratumumab for…